16405 Abrocitinib treatment in patients with moderate to severe atopic dermatitis: Consistency of efficacy responses from randomized, controlled phase 3 and phase 2b clinical trials
Simpson E, Gooderham M, King B, Taylor S, Rosmarin D, Tatulych S, Nduaka C, Williams D, Zhang W, Rojo R. 16405 Abrocitinib treatment in patients with moderate to severe atopic dermatitis: Consistency of efficacy responses from randomized, controlled phase 3 and phase 2b clinical trials. Journal Of The American Academy Of Dermatology 2020, 83: ab62. DOI: 10.1016/j.jaad.2020.06.336.Peer-Reviewed Original Research